Lanthanum carbonate (Fosrenol®):: a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients

Approximately 70% of patients with end-stage renal disease and dialysis have hyperphosphataemia, which is associated with renal osteodystrophy, metastatic calcification and increased mortality and morbidity. Despite dietary restriction and dialysis, most patients will require a phosphate-binding agent to treat this condition. However, phosphate control has not significantly improved over the last two decades, mainly because of the lack of an ideal phosphate-binding agent. Aluminium-based and calcium-based agents are associated with major side-effects despite their efficacy. Although sevelamer hydrochloride represents a step forward in the management of hyperphosphataemia, it has drawbacks and therefore is not the ideal phosphate binder. Lanthanum carbonate is a non-calcium, non-aluminium phosphate-binding agent. It has shown to be effective, well-tolerated and has a positive effect on bone histology.